Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 9, 2016, Pages 5198-5207

  Li, Wei ^a   Obregón Henao, Andrés ^a   Wallach, Joshua B ^b   North, E Jeffrey ^c,d   Lee, Richard E ^c   Gonzalez Juarrero, Mercedes ^a   Schnappinger, Dirk ^b   Jackson, Mary ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; MMPL3 PROTEIN; MYCOLIC ACID; UNCLASSIFIED DRUG; CARRIER PROTEIN; CIPROFLOXACIN; DOXYCYCLINE; ISONIAZID; MMPL3 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; FEMALE; IN VITRO STUDY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; TREATMENT DURATION; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENE SILENCING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; LUNG; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DOXYCYCLINE; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; ISONIAZID; LUNG; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84983509267     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00826-16     Document Type: Article

References (44)

1. World Health Organization. 2015. Global tuberculosis report 2015. World Health Organization, Geneva, Switzerland.
2. Sala C, Hartkoorn RC. 2011. Tuberculosis drugs: new candidates and how to find more. Future Microbiol 6:617-633. http://dx.doi.org/10.2217/fmb.11.46.
3. Jackson M, McNeil MR, Brennan PJ. 2013. Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis. Future Microbiol 8:855-875. http://dx.doi.org/10.2217/fmb.13.52.
4. Ballell L, Bates RH, Young RJ, Alvarez-Gomez D, Alvarez-Ruiz E, Barroso V, Blanco D, Crespo B, Escribano J, Gonzalez R, Lozano S, Huss S, Santos-Villarejo A, Martin-Plaza JJ, Mendoza A, Rebollo-Lopez MJ, Remuinan-Blanco M, Lavandera JL, Perez-Herran E, Gamo-Benito FJ, Garcia-Bustos JF, Barros D, Castro JP, Cammack N. 2013. Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMed- Chem 8:313-321. http://dx.doi.org/10.1002/cmdc.201200428.
5. Grzegorzewicz AE, Pham H, Gundi VA, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Korduláková J, Chavadi SS, Morisseau C, Lenaerts AJ, Lee RE, McNeil MR, Jackson M. 2012. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 8:334-341. http://dx.doi.org/10.1038/nchembio.794.
6. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE, III, Boshoff HI. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:1797-1809. http://dx.doi.org/10.1128/AAC.05708-11.
7. La Rosa V, Poce G, Canseco JO, Buroni S, Pasca MR, Biava M, Raju RM, Porretta GC, Alfonso S, Battilocchio C, Javid B, Sorrentino F, Ioerger TR, Sacchettini JC, Manetti F, Botta M, De Logu A, Rubin EJ, De Rossi E. 2012. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 56:324-331. http://dx.doi.org/10.1128/AAC.05270-11.
8. Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M, Wivagg C, Silvis M, Kazyanskaya E, Aquadro J, Golas A, Fitzgerald M, Dai H, Zhang L, Hung DT. 2012. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol 7:1377-1384. http://dx.doi.org/10.1021/cb300151m.
9. Poce G, Bates RH, Alfonso S, Cocozza M, Porretta GC, Ballell L, Rullas J, Ortega F, De Logu A, Agus E, La Rosa V, Pasca MR, De Rossi E, Wae B, Franzblau SG, Manetti F, Botta M, Biava M. 2013. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS One 8:e56980. http://dx.doi.org/10.1371/journal.pone.0056980.
10. Remuinan MJ, Perez-Herran E, Rullas J, Alemparte C, Martinez-Hoyos M, Dow DJ, Afari J, Mehta N, Esquivias J, Jimenez E, Ortega-Muro F, Fraile-Gabaldon MT, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, Minick DJ, Cacho M, Rebollo-Lopez MJ, Gonzalez C, Sousa V, Angulo-Barturen I, Mendoza-Losana A, Barros D, Besra GS, Ballell L, Cammack N. 2013. Tetrahydropyrazolo[1,5-a]pyrimidine-3- carboxamide and N-benzyl-6′,7′-dihydrospiro[piperidine-4,4′-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS One 8:e60933. http://dx.doi.org/10.1371/journal.pone.0060933.
11. Ioerger TR, O'Malley T, Liao R, Guinn KM, Hickey MJ, Mohaideen N, Murphy KC, Boshoff HI, Mizrahi V, Rubin EJ, Sassetti CM, Barry CE, III, Sherman DR, Parish T, Sacchettini JC. 2013. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS One 8:e75245. http://dx.doi.org/10.1371/journal.pone.0075245.
12. Lun S, Guo H, Onajole OK, Pieroni M, Gunosewoyo H, Chen G, Tipparaju SK, Ammerman NC, Kozikowski AP, Bishai WR. 2013. Indoleamides are active against drug-resistant Mycobacterium tuberculosis. Nat Commun 4:2907.
13. Rao SP, Lakshminarayana SB, Kondreddi RR, Herve M, Camacho LR, Bifani P, Kalapala SK, Jiricek J, Ma NL, Tan BH, Ng SH, Nanjundappa M, Ravindran S, Seah PG, Thayalan P, Lim SH, Lee BH, Goh A, Barnes WS, Chen Z, Gagaring K, Chatterjee AK, Pethe K, Kuhen K, Walker J, Feng G, Babu S, Zhang L, Blasco F, Beer D, Weaver M, Dartois V, Glynne R, Dick T, Smith PW, Diagana TT, Manjunatha UH. 2013. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis. Sci Transl Med 5:214ra168. http://dx.doi.org/10.1126/scitranslmed.3007355.
14. Tantry SJ, Degiacomi G, Sharma S, Jena LK, Narayan A, Guptha S, Shanbhag G, Menasinakai S, Mallya M, Awasthy D, Balakrishnan G, Kaur P, Bhattacharjee D, Narayan C, Reddy J, Naveen Kumar CN, Shandil R, Boldrin F, Ventura M, Manganelli R, Hartkoorn RC, Cole ST, Panda M, Markad SD, Ramachandran V, Ghorpade SR, Dinesh N. 2015. Whole cell screen based identification of spiropiperidines with potent antitubercular properties. Bioorg Med Chem Lett 25:3234-3245. http://dx.doi.org/10.1016/j.bmcl.2015.05.087.
15. Hoffmann C, Leis A, Niederweis M, Plitzko JM, Engelhardt H. 2008. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc Natl Acad Sci U S A 105:3963-3967. http://dx.doi.org/10.1073/pnas.0709530105.
16. Zuber B, Chami M, Houssin C, Dubochet J, Griffiths G, Daffé M. 2008. Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J Bacteriol 190:5672-5680. http://dx.doi.org/10.1128/JB.01919-07.
17. Li W, Upadhyay A, Fontes FL, North EJ, Wang Y, Crans DC, Grzegorzewicz AE, Jones V, Franzblau SG, Lee RE, Crick DC, Jackson M. 2014. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:6413-6423. http://dx.doi.org/10.1128/AAC.03229-14.
18. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes F, Yang H, Rao G, Zhu W, Gulati A, No JH, Cintra G, Bogue S, Liu Y-L, Molohon K, Orlean P, Mitchell DA, Freitas-Junior L, Ren F, Sun H, Jiang T, Li Y, Guo R-T, Cole ST, Gennis RB, Crick DC, Oldfield E. 2014. Multi-target drug discovery for tuberculosis and other infectious diseases. J Med Chem 57:3126-3139. http://dx.doi.org/10.1021/jm500131s.
19. Sacksteder KA, Protopopova M, Barry CE, III, Andries K, Nacy CA. 2012. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol 7:823-837. http://dx.doi.org/10.2217/fmb.12.56.
20. Kim JH, O'Brien KM, Sharma R, Boshoff HI, Rehren G, Chakraborty S, Wallach JB, Monteleone M, Wilson DJ, Aldrich CC, Barry CE, III, Rhee KY, Ehrt S, Schnappinger D. 2013. A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci U S A 110:19095-19100. http://dx.doi.org/10.1073/pnas.1315860110.
21. Schnappinger D, O'Brien KM, Ehrt S. 2015. Construction of conditional knockdown mutants in mycobacteria. Methods Mol Biol 1285:151-175. http://dx.doi.org/10.1007/978-1-4939-2450-9-9.
22. Jackson M, Camacho LR, Gicquel B, Guilhot C. 2001. Gene replacement and transposon delivery using the negative selection marker sacB. Methods Mol Med 54:59-75.
23. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of non-replicating persistence. Infect Immun 64:2062-2069.
24. Stadthagen G, Korduláková J, Griffin R, Constant P, Bottova I, Barilone N, Gicquel B, Daffé M, Jackson M. 2005. p-Hydroxybenzoic acid synthesis in Mycobacterium tuberculosis. J Biol Chem 280:40699-40706. http://dx.doi.org/10.1074/jbc.M508332200.
25. Martin A, Camacho M, Portaels F, Palomino J-C. 2003. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother 47:3616-3619. http://dx.doi.org/10.1128/AAC.47.11.3616-3619.2003.
26. Orme I, Gonzalez-Juarrero M. 2007. Animal models of M. tuberculosis infection. Curr Protoc Microbiol Chapter 10:Unit 10A.5.
27. Puckett S, Trujillo C, Eoh H, Marrero J, Spencer J, Jackson M, Schnappinger D, Rhee K, Ehrt S. 2014. Inactivation of fructose-1,6- bisphosphate aldolase prevents optimal co-catabolism of glycolytic and gluconeogenic carbon substrates in Mycobacterium tuberculosis. PLoS Pathog 10:e1004144. http://dx.doi.org/10.1371/journal.ppat.1004144.
28. Carel C, Nukdee K, Cantaloube S, Bonne M, Diagne CT, Laval F, Daffé M, Zerbib D. 2014. Mycobacterium tuberculosis proteins involved in mycolic acid synthesis and transport localize dynamically to the old growing pole and septum. PLoS One 9:e97148. http://dx.doi.org/10.1371/journal.pone.0097148.
29. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, Lee EG, Park SK, Raleigh JA, Cho SN, McMurray DN, Flynn JL, Barry CE, III. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76:2333-2340. http://dx.doi.org/10.1128/IAI.01515-07.
30. Barry CE, III, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7:845-855. http://dx.doi.org/10.1038/nrmicro2236.
31. Zhang Y, Yew WW, Barer MR. 2012. Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 56:2223-2230. http://dx.doi.org/10.1128/AAC.06288-11.
32. Abrahams GL, Kumar A, Savvi S, Hung AW, Wen S, Abell C, Barry CE, III, Sherman DR, Boshoff HI, Mizrahi V. 2012. Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem Biol 19:844-854. http://dx.doi.org/10.1016/j.chembiol.2012.05.020.
33. Krieger IV, Freundlich JS, Gawandi VB, Roberts JP, Gawandi VB, Sun Q, Owen JL, Fraile MT, Huss SI, Lavandera JL, Ioerger TR, Sacchettini JC. 2012. Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase. Chem Biol 19:1556-1567. http://dx.doi.org/10.1016/j.chembiol.2012.09.018.
34. Kumar A, Zhang M, Zhu L, Liao RP, Mutai C, Hafsat S, Sherman DR, Wang MW. 2012. High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity. PLoS One 7:e39961. http://dx.doi.org/10.1371/journal.pone.0039961.
35. Brown JR, North EJ, Hurdle JG, Morisseau C, Scarborough JS, Sun D, Korduláková J, Scherman MS, Jones V, Grzegorzewicz A, Crew RM, Jackson M, McNeil MR, Lee RE. 2011. The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg Med Chem 19: 5585-5595. http://dx.doi.org/10.1016/j.bmc.2011.07.034.
36. Domenech P, Reed MB, Barry CE, III. 2005. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun 73:3492-3501. http://dx.doi.org/10.1128/IAI.73.6.3492-3501.2005.
37. Park SW, Klotzsche M, Wilson DJ, Boshoff HI, Eoh H, Manjunatha U, Blumenthal A, Rhee KY, Barry CE, III, Aldrich CC, Ehrt S, Schnappinger D. 2011. Evaluating the sensitivity of Mycobacterium tuberculosis to biotin deprivation using regulated gene expression. PLoS Pathog 7:e1002264. http://dx.doi.org/10.1371/journal.ppat.1002264.
38. Kolly GS, Boldrin F, Sala C, Dhar N, Hartkoorn RC, Ventura M, Serafini A, McKinney JD, Manganelli R, Cole ST. 2014. Assessing the essentiality of the decaprenyl-phospho-D-arabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants. Mol Microbiol 92:194-211. http://dx.doi.org/10.1111/mmi.12546.
39. Boldrin F, Ventura M, Degiacomi G, Ravishankar S, Sala C, Svetliková Z, Ambady A, Dhar N, Korduláková J, Zhang M, Serafini A, Vishwas KG, Kolly GS, Kumar N, Palu G, Guerin ME, Mikušová K, Cole ST, Manganelli R. 2014. The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo. J Bacteriol 196:3441-3451. http://dx.doi.org/10.1128/JB.01346-13.
40. Tullius MV, Harmston CA, Owens CP, Chim N, Morse RP, McMath LM, Iniguez A, Kimmey JM, Sawaya MR, Whitelegge JP, Horwitz MA, Goulding CW. 2011. Discovery and characterization of a unique mycobacterial heme acquisition system. Proc Natl Acad Sci U S A 108:5051-5056. http://dx.doi.org/10.1073/pnas.1009516108.
41. Owens CP, Chim N, Graves AB, Harmston CA, Iniguez A, Contreras H, Liptak MD, Goulding CW. 2013. The Mycobacterium tuberculosis secreted protein Rv0203 transfers heme to membrane proteins MmpL3 and MmpL11. J Biol Chem 288:21714-21728. http://dx.doi.org/10.1074/jbc.M113.453076.
42. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. 2002. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43:717-731. http://dx.doi.org/10.1046/j.1365-2958.2002.02779.x.
43. Voskuil MI. 2004. Mycobacterium tuberculosis gene expression during environmental conditions associated with latency. Tuberculosis (Edinb) 84:138-143. http://dx.doi.org/10.1016/j.tube.2003.12.008.
44. Lenaerts A, Barry CE, III, Dartois V. 2015. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev 264:288-307. http://dx.doi.org/10.1111/imr.12252.